Organon on June 3 celebrated the launch of the global women’s health company with employees and women from around the world, as the Organon executive leadership team rang the opening bell at the New York Stock Exchange (NYSE). Recognizing the need to listen to and act on women’s experiences to address the challenges in women’s health, Organon gathered voices from around the world to create the “Wall of Voices,” a multimedia installation outside of the NYSE.
On the cusp of the 2021 American Society of Clinical Oncology meeting, more companies are announcing data presentations that will be made over the four-day conference as BioSpace continues to take a look at some of the data that will be shared.
San Diego-based Ligand Pharmaceuticals is acquiring San Diego-based Pfenex for a total deal transaction of up to $516 million.
Numerous major global biopharma companies reported first-quarter 2020 earnings. Typically, the COVID-19 pandemic has affected the companies, although not necessarily in a straightforward way. Many of the companies reported increased sales for the quarter as customers increased stockpiles and inventory in preparation for the pandemic, while other forms of sales and clinical trials were negatively impacted. Here’s a look.
The European Commission approved Pfizer Inc.’s Ruxience (rituximab) – a monoclonal antibody and biosimilar to MabThera – for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis, and pemphigus vulgaris.
Merck is spinning off products from the company’s Women’s Health, Legacy Brands and Biosimilars businesses.
China’s Innovent Biologics forged a licensing agreement with biosimilar-focused Coherus BioSciences to commercialize Innovent’s biosimilar candidate to Avastin (bevacizumab) in the United States and Canada.
The U.S. Food and Drug Administration approved Amgen Inc.’s biosimilar copy of Johnson & Johnson’s blockbuster rheumatoid arthritis (RA) drug Remicade.
China’s Bio-Thera Solutions Ltd. won a regulatory approval for the company’s version of AbbVie Inc.’s blockbuster rheumatoid arthritis treatment Humira, paving the way for the first such biosimilar to enter the world’s second-largest drug market.
Novartis won FDA approval for a long-delayed version of Amgen’s $4 billion seller Neulasta drug, helping the Swiss drugmaker in an uphill battle to sell copies of rivals’ blockbusters in the U.S.